Clarus Therapeutics Submits New Drug Application for Rextoro (formerly CLR-610) for the treatment of Low Testosterone
13 janv. 2014 09h00 HE
|
Clarus Therapeutics Holdings, Inc.
Northbrook, Ill, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today announced the submission of a New
Drug Application (NDA) for Rextoro™ (formerly CLR-610), the
Company's oral...